GlaxoSmithKline PakistanKAR:GLAXO +0.75%93 3-Year ROIIC % is 64.82 as of Dec. 2025, which is 158% above its 10-year median of 25.12. GuruFocus rates KAR:GLAXO with a GF Score™ of 93/100 and a GF Value™ of ₨323.92 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 944 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks better than 85.81% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
GlaxoSmithKline Pakistan's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 64.82%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for GlaxoSmithKline Pakistan's 3-Year ROIIC % or its related term are showing as below:
KAR:GLAXO's 3-Year ROIIC % is ranked better than 85.81% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs KAR:GLAXO: 64.82
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
GlaxoSmithKline Pakistan 3-Year ROIIC % Related Terms
GlaxoSmithKline Pakistan 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:GLAXO vs ZTS, UTHR, VTRS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a 3-Year ROIIC % of 64.82 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on GlaxoSmithKline Pakistan and its competitors. This is 158% above median its historical median of 25.12. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #134 out of 944 companies in the Drug Manufacturers industry, placing it in the top 14.2%.
Is GlaxoSmithKline Pakistan's 3-Year ROIIC % too high?
GlaxoSmithKline Pakistan's current 3-Year ROIIC % of 64.82 is 158% above median its 10-year median of 25.12. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. GlaxoSmithKline Pakistan's value of 64.82 is 1683.2% above this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #134 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #134 out of 944 companies for 3-Year ROIIC %. This places GlaxoSmithKline Pakistan in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.64. GlaxoSmithKline Pakistan's value of 64.82 is 1683.2% above this benchmark. While the company's 10-year median is 25.12 vs. the industry median of 3.64, GlaxoSmithKline Pakistan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current 3-Year ROIIC % of 64.82 is 1683.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current 3-Year ROIIC % is 64.82, which is 158% above median its own 10-year median of 25.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨323.92, compared to a current price of ₨373.01 — trading 15.2% above its estimated fair value. The current 3-Year ROIIC % is 64.82, which is 158% above median its 10-year median of 25.12 and 1683.2% above the Drug Manufacturers industry median of 3.64. GlaxoSmithKline Pakistan's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current 3-Year ROIIC % is 64.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨373.01 is trading 15.2% above its estimated GF Value™ of ₨323.92.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
3-Year ROIIC %: 64.82 (158% above median its 10-year median of 25.12)
GF Value™: ₨323.92 vs. price of ₨373.01 (15.2% above fair value)
Industry Position: 1683.2% above the Drug Manufacturers median (#134 of 944)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
93GF Score
Get the complete analysis for KAR:GLAXO
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
